Trial · NCT02600897
Adverse event totals27
The totals the trial posted for each group.
1 to 20 of 27
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | 1 | 3 |
| Total, all-cause mortality | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | 2 | 4 |
| Total, all-cause mortality | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | 1 | 3 |
| Total, all-cause mortality | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | 2 | 6 |
| Total, all-cause mortality | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | 3 | 3 |
| Total, all-cause mortality | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | 2 | 5 |
| Total, all-cause mortality | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | 10 | 10 |
| Total, all-cause mortality | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | 7 | 40 |
| Total, all-cause mortality | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | 20 | 39 |
| Total, other adverse events | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | 3 | 3 |
| Total, other adverse events | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | 4 | 4 |
| Total, other adverse events | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | 3 | 3 |
| Total, other adverse events | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | 6 | 6 |
| Total, other adverse events | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | 3 | 3 |
| Total, other adverse events | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | 5 | 5 |
| Total, other adverse events | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | 9 | 10 |
| Total, other adverse events | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | 40 | 40 |
| Total, other adverse events | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | 37 | 39 |
| Total, serious adverse events | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | 3 | 3 |
| Total, serious adverse events | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | 2 | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02600897/event-totals